Teva Pharmaceutical Industries 관리

관리 기준 확인 2/4

Teva Pharmaceutical Industries CEO는 Richard Francis, Jan2023 에 임명되었습니다 의 임기는 1.92 년입니다. 총 연간 보상은 $ 25.71M, 6.2% 로 구성됩니다. 6.2% 급여 및 93.8% 보너스(회사 주식 및 옵션 포함). 는 € 2.68M 가치에 해당하는 회사 주식의 0.011% 직접 소유합니다. 2.68M. 경영진과 이사회의 평균 재임 기간은 각각 2.8 년과 7.4 년입니다.

주요 정보

Richard Francis

최고 경영자

US$25.7m

총 보상

CEO 급여 비율	6.2%
CEO 임기	1.9yrs
CEO 소유권	0.01%
경영진 평균 재임 기간	2.8yrs
이사회 평균 재임 기간	7.4yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Richard Francis 의 보수는 Teva Pharmaceutical Industries 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-US$959m
Jun 30 2024	n/a	n/a	-US$453m
Mar 31 2024	n/a	n/a	-US$478m
Dec 31 2023	US$26m	US$2m	-US$559m

보상 대 시장: Richard 의 총 보상 ($USD 25.71M )은 Austrian 시장( $USD 4.41M ).

보상과 수익: Richard 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.

CEO

Richard Francis (56 yo)

1.9yrs

테뉴어

US$25,706,880

보상

Mr. Richard D. Francis serves as President and Chief Executive Officer at Teva Pharmaceutical Industries Limited since January 01, 2022 and serves as its Director. Mr. Francis served as Division Head and C...

리더십 팀

이름	위치	테뉴어	보상	소유권
Richard Francis	President	1.9yrs	US$25.71m	0.011% € 2.7m
Eliyahu Kalif	Executive VP & CFO	5yrs	US$4.94m	0.064% € 15.7m
Mark Sabag	Executive Vice President of International Markets Commercial	3.3yrs	US$3.73m	0.028% € 6.9m
Richard Daniell	Executive Vice President of European Commercial	7.1yrs	US$5.16m	0% € 0
Matthew Shields	Executive Vice President of Global Operations	less than a year	데이터 없음	데이터 없음
Amir Weiss	Senior VP & Chief Accounting Officer	3.1yrs	데이터 없음	0.00046% € 113.3k
Christopher Stevo	Senior Vice President of Investor Relations & Competitive Intelligence	no data	데이터 없음	데이터 없음
Kathleen Veit	Senior Vice President	2.4yrs	데이터 없음	데이터 없음
David Mcavoy	Executive VP & Chief Legal Officer	less than a year	데이터 없음	데이터 없음
Placid Jover	Executive VP & CHRO	less than a year	데이터 없음	데이터 없음
Kevin Mannix	Senior Vice President of Investor Relations	no data	데이터 없음	데이터 없음
Nir Baron	Senior VP & Chief Internal Auditor	10.6yrs	데이터 없음	데이터 없음

2.8yrs

평균 재임 기간

53yo

평균 연령

경험이 풍부한 관리: TEVA 의 관리팀은 경험 ( 2.8 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Richard Francis	President	no data	US$25.71m	0.011% € 2.7m
Sol Barer	Independent Chairman of the Board	9.9yrs	US$539.99k	0.036% € 8.9m
Amir Elstein	Independent Director	15.9yrs	US$340.00k	0.18% € 45.5m
Gerald Lieberman	Independent Director	9.3yrs	US$355.00k	0.0093% € 2.3m
Roberto Mignone	Independent Director	7.4yrs	US$340.00k	0.0084% € 2.1m
Rosemary Crane	Independent Director	9.3yrs	US$330.00k	0.0091% € 2.2m
Janet Vergis	Independent Director	4.5yrs	US$325.46k	0.0056% € 1.4m
Chen Lichtenstein	Independent Director	no data	데이터 없음	데이터 없음
Tal Zaks	Independent Director	3.2yrs	US$330.00k	0.0043% € 1.1m
Perry Nisen	Independent Director	7.4yrs	US$327.87k	0.0084% € 2.1m
Ronit Satchi-Fainaro	Independent Director	6.5yrs	US$315.25k	0.0078% € 1.9m
Varda Shalev	Independent Director	1.3yrs	US$176.66k	0.0011% € 278.3k

7.4yrs

평균 재임 기간

62yo

평균 연령

경험이 풍부한 이사회: TEVA 의 이사회는 경험(평균 재직 기간 7.4 년)으로 간주됩니다.

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2024/12/27 11:43
장 마감 주가	2024/12/23 00:00
수익	2024/09/30
연간 수익	2023/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Teva Pharmaceutical Industries Limited 60 애널리스트 중 9 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Jasper Hellweg	Argus Research Company
Richard Silver	Barclays
Balaji Prasad	Barclays

Teva Pharmaceutical Industries 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Teva Pharmaceutical Industries Limited Announces Management Changes, Effective June 3, 2024

Teva Pharmaceutical Industries Limited, Annual General Meeting, Jun 06, 2024

Teva Pharmaceutical Industries Ltd. Appoints R. Ananthanarayanan (Ananth) as CEO of Its Teva Active Pharmaceutical Ingredients Business

Teva Announces Changes to Executive Management Team

Teva Pharmaceutical Industries Limited Appoints Varda Shalev as Member of the Board, Effective September 1, 2023

Teva Announces Appointment of Dr. Angus Grant to Executive Vice President, Business Development, Effective August 1, 2023

Recent updates

Teva Pharmaceutical Industries Limited to Report Q4, 2024 Results on Jan 29, 2025

New major risk - Share price stability

Third quarter 2024 earnings released: US$0.39 loss per share (vs US$0.071 profit in 3Q 2023)

Teva Pharmaceuticals Limited Unveils New Phase 3 Positive Results for Olanzapine Lai, and Presents Real-World Data on Uzedy At Psych Congress 2024

Alvotech and Teva Pharmaceutical Industries Ltd. Announce U.S. FDA Approval of Additional Presentation of SELARSDI (ustekinumab-aekn)

Teva Pharmaceutical Industries Limited to Report Q3, 2024 Results on Nov 06, 2024

Second quarter 2024 earnings released: US$0.75 loss per share (vs US$0.77 loss in 2Q 2023)

Teva Pharmaceuticals and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflammatory Bowel Disease

Teva Pharmaceutical Industries Limited Announces First Phase 3 Evidence of Efficacy and Safety of an Anti-CGRP Monoclonal Antibody in Children in AJOVY (fremanezumab) Space Trial for Prevention of Episodic Migraine

Teva Pharmaceutical Industries Limited to Report Q2, 2024 Results on Jul 31, 2024

Teva Pharmaceutical Industries Ltd Announces New AJOVY® (Fremanezumab) Migraine Prevention Data Challenges Treatment Pauses

Teva Pharmaceutical Industries Limited Announces Launch of Authorized Generic of Victoza® (Liraglutide Injection 1.8Mg), in the United States

Teva Pharmaceutical Industries Limited Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day)

Teva Pharmaceutical Industries Limited Announces Management Changes, Effective June 3, 2024

Teva Pharmaceutical Industries Limited Reaffirms Earnings Guidance for the Full Year 2024

First quarter 2024 earnings released: US$0.12 loss per share (vs US$0.18 loss in 1Q 2023)

Teva Pharmaceutical Industries Limited, Annual General Meeting, Jun 06, 2024

Teva Confirms Efficacy and Safety of AJOVY for the Prevention of Migraine with Results from Phase 3 Trial in China

Teva Pharmaceutical Industries Limited to Report Q1, 2024 Results on May 08, 2024

Teva Pharmaceutical Industries Limited Reports Impairment Charges for the Fourth Quarter Ended December 31, 2023

Full year 2023 earnings released: US$0.50 loss per share (vs US$2.12 loss in FY 2022)

Teva Pharmaceutical Industries Limited Announces Earnings Guidance for Full Year 2024

New major risk - Share price stability

Court for the District of New Jersey Issues A Decision That Teva Pharmaceuticals Does Not Infringe Any Asserted Claims of Corcept Therapeutics Incorporated’s U.S. Patents

Teva Pharmaceutical Industries Limited Announces Post Hoc Phase 3 Data Analysis Shows AJOVY (Fremanezumab) Reduced Migraine Attacks in Adults with Migraine and Co-Morbid Obesity

Third quarter 2023 earnings released: EPS: US$0.071 (vs US$0.05 in 3Q 2022)

Teva Pharmaceutical Industries Ltd. Appoints R. Ananthanarayanan (Ananth) as CEO of Its Teva Active Pharmaceutical Ingredients Business

Teva Pharmaceutical Industries Limited Announces Phase IV Unite Study Shows Ajovy® (Fremanezumab) Reduced Migraine Attacks and Depression Symptoms in Migraine Sufferers with Major Depressive Disorder

Teva Pharmaceutical Industries Limited to Report Q3, 2023 Results on Nov 08, 2023

New major risk - Share price stability

Teva Announces Changes to Executive Management Team

Teva Pharmaceutical Industries Limited Appoints Varda Shalev as Member of the Board, Effective September 1, 2023

Teva Pharmaceutical Industries Limited Reports Impairment Charges for the Second Quarter Ended June 30, 2023

Second quarter 2023 earnings released: US$0.77 loss per share (vs US$0.21 loss in 2Q 2022)

Teva Announces Appointment of Dr. Angus Grant to Executive Vice President, Business Development, Effective August 1, 2023

Teva Pharmaceutical Industries Limited to Report Q2, 2023 Results on Aug 02, 2023

Teva Pharmaceutical Industries Ltd. Announces Further Positive Data from the Pan-European Research Study

Teva to Present Data at the 2023 American Headache Society Annual Scientific Meeting Demonstrating AJOVY

Teva Pharmaceuticals Presents Real-World Data for Austedo (Deutetrabenazine) Tablets with 4-Week Patient Titration Kit At Psych Congress Elevate 2023

Teva to Present Data Demonstrating UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolonged Time to Impending Relapse for Adults with Schizophrenia at the American Psychiatric Association’s 2023 Annual Meeting

Teva Pharmaceutical Industries Limited Announces That Once-Daily Austedoxr (Deutetrabenazine) Extended-Release Tablets Are Now Available for Adults in the United States

Teva Pharmaceutical Industries Limited Reaffirms Earnings Guidance for the Full Year 2023

First quarter 2023 earnings released: US$0.19 loss per share (vs US$0.86 loss in 1Q 2022)

Full year 2022 earnings released: US$2.12 loss per share (vs US$0.38 profit in FY 2021)

Teva Pharmaceutical Industries Limited Provides Earnings Guidance for the Year 2023

Teva Pharmaceutical Industries Limited to Report Q4, 2022 Results on Feb 08, 2023

Karo Pharma AB (publ) agreed to acquire of Six brands of Teva for DKK 84 million.

Teva Pharmaceutical Industries Limited Appoints Richard Francis as President, Effective January 1, 2023

Third quarter 2022 earnings released: EPS: US$0.05 (vs US$0.27 in 3Q 2021)

Teva Pharmaceutical Industries Limited Revises Earnings Guidance for the Year 2022

Teva Pharmaceutical Industries Limited Reaches Agreement with Arkansas to Settle the State’s Price Fixing Claims

Teva Pharmaceutical Industries Limited to Report Q3, 2022 Results on Nov 03, 2022

Teva Pharmaceutical Industries Limited Presents Studies of Effectiveness of AJOVY for Treatment of Migraine in Patients with Co-morbid Depression

Exelixis, Inc. Files Complaint in the United States District Court for the District of Delaware for Patent Infringement against Teva Pharmaceutical Industries Limited, Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc

Teva Pharmaceutical Industries Limited Announces European Commission Grants Marketing Authorization for Ranivisio (Ranibizumab), for Age-Related Macular Degeneration (AMD) the Most Common Cause of Blindness in Developed Countries

Teva Pharmaceutical Industries Limited Provides Earnings Guidance for the Year 2022

Teva Pharmaceutical Industries Limited Announces Impairment Charges for the Second Quarter Ended June 30, 2022

Second quarter 2022 earnings released: US$0.21 loss per share (vs US$0.19 profit in 2Q 2021)

Teva Pharmaceutical Industries Limited Appoints Eric A. Hughes as Executive Vice President, Global R&D and Chief Medical Officer

Teva Pharmaceutical Industries Limited to Report Q2, 2022 Results on Jul 27, 2022

Teva Pharmaceutical Industries Limited Welcomes the UK Medicines & Healthcare Regulatory Agency Decision to Grant A Licence for Ongavia

Teva Pharmaceutical Industries Limited Revises Earnings Guidance for the Full Year 2022

First quarter 2022 earnings released: US$0.86 loss per share (vs US$0.07 profit in 1Q 2021)

Teva Pharmaceutical Industries Limited to Report Q1, 2022 Results on May 03, 2022

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Teva Pharmaceutical Industries Limited Provides Earnings Guidance for the Year 2022

Teva Announces Launch of First-To-Market Generic Version of Narcan (Naloxone Hydrochloride Nasal Spray), in the U.S

Chief Accounting Officer Andrew Weil has left the company

Third quarter 2021 earnings released: EPS US$0.27 (vs US$3.97 loss in 3Q 2020)